<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007951</url>
  </required_header>
  <id_info>
    <org_study_id>GBP510_003</org_study_id>
    <nct_id>NCT05007951</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)</brief_title>
  <official_title>A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coalition for Epidemic Preparedness Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, randomized, active-controlled, observer-blind, parallel-group,&#xD;
      multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant&#xD;
      nanoparticle vaccine adjuvanted with AS03 (GBP510) to ChAdOx1-S in adults aged 18 years and&#xD;
      older.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the immunogenicity and safety of SK SARS-CoV-2&#xD;
      recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) in adults aged 18 years and&#xD;
      older.&#xD;
&#xD;
      This study includes 2-dose schedule (28-day interval) of GBP510 and ChAdOx1-S. Participants&#xD;
      are expected to participate for up to a maximum of approximately 13 months. A 12-month study&#xD;
      follow-up after the 2nd vaccination will be conducted.&#xD;
&#xD;
      International Vaccine Institute (IVI) conducts GBP510_003 trial as co-sponsor with SK&#xD;
      bioscience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays</measure>
    <time_frame>2 weeks post 2nd vaccination</time_frame>
    <description>For Cohort 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline</measure>
    <time_frame>2 weeks post 2nd vaccination</time_frame>
    <description>Fo Cohort 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of SARS-CoV-2 Receptor-Binding Domain(RBD)-binding IgG antibody measured by Enzyme-Linked Immunosorbent Assay (ELISA) at each time point post-vaccination</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise(GMFR) of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from baseline</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ≥ 4-fold rise SARS-CoV-2 RBD-binding IgG titer from baseline</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays from baseline</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated response for both Th1 and Th2 cytokines measured by Enzyme-Linked ImmunoSpot (ELISpot)/ FluoroSpot, and for both CD4+ and CD8+ T-cells measured by Fluorescence-activated cell sorting(FACS)</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of immediate systemic reactions in the 30 minutes post each vaccination</measure>
    <time_frame>Through 30 minutes post each vaccination</time_frame>
    <description>For all Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local Adverse Events(AEs)</measure>
    <time_frame>Through 7 days post each vaccination</time_frame>
    <description>For all Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited systemic AEs</measure>
    <time_frame>Through 7 days post each vaccination</time_frame>
    <description>For all Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited AEs</measure>
    <time_frame>Through 28 days post each vaccination</time_frame>
    <description>For all Cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse events(SAEs), Medically attended Adverse Events(MAAEs), AEs leading to study withdrawal, and Adverse Events of Special Interests(AESIs)</measure>
    <time_frame>Through Day 365 post last vaccination</time_frame>
    <description>For all Cohort</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3990</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Test group (GBP510) - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunogenicity Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (ChAdOx1-S) - Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunogenicity Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group (GBP510) - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (ChAdOx1-S) - Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Safety Cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)</intervention_name>
    <description>injection volume of 0.5mL on days 0 and 28</description>
    <arm_group_label>Test group (GBP510) - Cohort 1</arm_group_label>
    <arm_group_label>Test group (GBP510) - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1-S not less than 2.5 × 10^8 infectious units</intervention_name>
    <description>injection volume of 0.5mL on days 0 and 28</description>
    <arm_group_label>Control group (ChAdOx1-S) - Cohort 1</arm_group_label>
    <arm_group_label>Control group (ChAdOx1-S) - Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 years of age and older, at the time of signing the informed&#xD;
             consent;&#xD;
&#xD;
          -  Participants who are healthy or medically stable as determined by medical evaluation&#xD;
             including medical history, physical examination, clinical laboratory tests, and&#xD;
             medical judgement of the investigator;&#xD;
&#xD;
          -  Participants who are able to attend all scheduled visits and comply with all study&#xD;
             procedures;&#xD;
&#xD;
          -  Female participants of childbearing potential must agree to be heterosexually&#xD;
             inactive, or agree to consistently use at least one acceptable method of contraception&#xD;
             from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last&#xD;
             study vaccination;&#xD;
&#xD;
          -  Female participants with a negative urine or serum pregnancy test at screening;&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in&#xD;
             protocol;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile&#xD;
             illness (tympanic temperature &gt;38°C), or acute illness within 72 hours prior to the&#xD;
             1st study vaccination. A prospective participant should not be included until 72 hours&#xD;
             after the condition has resolved;&#xD;
&#xD;
          -  (Only for Cohort 1) Prior SARS-CoV-2 infection or vaccination confirmed by a positive&#xD;
             result of qualitative test for SARS-CoV-2 antibody using a rapid antibody kit at&#xD;
             screening;&#xD;
&#xD;
          -  History of virologically-confirmed SARS or MERS disease, or SARS / MERS vaccination;&#xD;
&#xD;
          -  History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease;&#xD;
&#xD;
          -  History of bleeding disorder or thrombocytopenia which is contraindicating&#xD;
             intramuscular vaccination;&#xD;
&#xD;
          -  History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis,&#xD;
             Guillain-Barre syndrome) to any vaccines or components of the study vaccine;&#xD;
&#xD;
          -  History of malignancy within 1 year prior to the 1st study vaccination (with the&#xD;
             exception of malignancy with minimal risk of recurrence at the discretion of the&#xD;
             investigator);&#xD;
&#xD;
          -  Significant unstable chronic or acute illness that, in the opinion of the&#xD;
             investigator, might pose a health risk to the participant if enrolled, or could&#xD;
             interfere with the protocol-specified activities, or interpretation of study results;&#xD;
&#xD;
          -  Any other conditions which, in the opinion of the investigator, might interfere with&#xD;
             the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or&#xD;
             psychiatric conditions);&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned&#xD;
             receipt of any vaccine from enrollment through 28 days after the last study&#xD;
             vaccination (Visit 7), except for influenza vaccination, which may be received at&#xD;
             least 2 weeks prior to the 1st study vaccination. This exception includes monovalent&#xD;
             pandemic influenza vaccines and multivalent influenza vaccines;&#xD;
&#xD;
          -  Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to&#xD;
             the 1st study vaccination;&#xD;
&#xD;
          -  Receipt of any medications or vaccinations intended to prevent COVID-19;&#xD;
&#xD;
          -  Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as&#xD;
             anticancer chemotherapy or radiation therapy; or long-term systemic corticosteroid&#xD;
             therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within&#xD;
             12 weeks prior to the 1st vaccination. The use of topical and nasal glucocorticoids&#xD;
             will be permitted;&#xD;
&#xD;
          -  Participation in another clinical study involving study intervention within 4 weeks&#xD;
             prior to the 1st study vaccination, or concurrent, planned participation in another&#xD;
             clinical study with study intervention during the study period.&#xD;
&#xD;
          -  Participants who are subjected to any global or local restrictions in place for use of&#xD;
             ChAdOx1-S (e.g. age, gender, or other specific population groups)&#xD;
&#xD;
          -  Investigators, or study staff who are directly involved in the conduct of this study&#xD;
             or supervised by the investigator, and their respective family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Jin Cheong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoonyeong Lee</last_name>
    <phone>+82 2-2008-2337</phone>
    <email>yoonyeong@sk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hostpital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou university hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha university hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha womans university medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym university medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea university Anam hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wonju severance christian hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Dniprodzerzhyns'k</city>
        <state>Dnipropetrovs'k</state>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Kropyvnytskyi</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial site</name>
      <address>
        <city>Hochiminh city</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

